QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How to Read an EMA Referral From a Pharmacovigilance Perspective

Test your understanding of the concepts covered by How to Read an EMA Referral From a Pharmacovigilance Perspective.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the appropriate approach to an apparent high-risk subgroup finding?

Accept it as definitive solely because the subgroup estimate is numerically large Assess prespecification, sample size, consistency, biological plausibility and possible confounding or chance Ignore it because subgroup results are never informative Use it immediately as proof that the medicine is contraindicated for the entire population

Question 2 of 10 Why should absolute risk be considered alongside relative risk in a referral assessment?

Relative risk is never useful in regulatory work A large relative increase may represent a small absolute excess, while a modest relative increase may affect many patients when exposure is widespread Absolute risk can be calculated from spontaneous report counts alone Absolute risk determines causality independently of study design

Question 3 of 10 Which regulatory measure most directly indicates that use under specified circumstances is considered unacceptable?

A warning A contraindication A routine pharmacovigilance study A general educational statement

Question 4 of 10 What does initiation of an EMA referral generally demonstrate about a safety concern?

That causality has been definitively established That a formal EU-level assessment is considered necessary That the marketing authorisation must be suspended That the suspected event has a known incidence rate

Question 5 of 10 What is the most appropriate conclusion from a negative clinical trial regarding a very rare serious adverse event?

The risk is definitively absent The trial may not have been sufficiently powered to exclude the risk The event must be unrelated to the medicine The trial result should always outweigh all other evidence

Question 6 of 10 Why should evidence from individual case reports, clinical trials and epidemiological studies not be treated as interchangeable?

They provide different types of information and have different strengths and limitations Only clinical trials can ever contribute to causality assessment Case reports are always more reliable than comparative studies Epidemiological studies are used only after a legal decision

Question 7 of 10 Which sequence best represents the usual conceptual progression of a complex safety referral?

Final decision, initial concern, evidence collection, scientific question Safety concern, regulatory questions, evidence assessment, uncertainty and benefit-risk, regulatory action Product information, spontaneous reports, legal basis, clinical phenotype Mechanism, Commission decision, notification, exposure assessment

Question 8 of 10 Why should evidence against a safety hypothesis be actively examined during referral analysis?

It helps determine how conflicting information and residual uncertainty were weighed It is required only when the referral is likely to end in withdrawal Negative evidence automatically invalidates all positive evidence It prevents regulators from considering serious outcomes

Question 9 of 10 Which statement correctly describes the relationship between PRAC and a subsequent CHMP or CMDh step?

PRAC's recommendation is always the final legally binding decision PRAC performs the relevant pharmacovigilance assessment, which may then enter a CHMP or CMDh regulatory pathway CHMP and CMDh are responsible for replacing the scientific assessment with a press release PRAC has no role in referrals involving pharmacovigilance data

Question 10 of 10 Which statement best describes the role of product-information changes in understanding an EMA referral?

They are administrative text changes unrelated to the scientific assessment They show how the risk conclusion was translated into operational conditions of clinical use They replace the need to examine benefit-risk reasoning They prove that every identified risk requires a contraindication

Knowledge Assessment: How to Read an EMA Referral From a Pharmacovigilance Perspective

Cookie Settings